Ridgeback Biotherapeutics

Ridgeback Biotherapeutics is a Miami-based biopharmaceutical company developing potential medicines for infectious diseases with limited treatment options. Its focus includes antiviral drug development for diseases such as Ebola and COVID-19. Ridgeback has partnered with other organizations, including Merck, on the development of molnupiravir, an oral antiviral investigated for COVID-19.